Product Description
Hydroxyprogesterone caproate injection is a man-made progestin hormone. It is used in pregnant women to help lower the risk of giving birth too early (preterm birth or giving birth less than 37 weeks of pregnancy). This medicine is given only to pregnant women who are pregnant with one baby and who have had a preterm delivery of one baby in the past. (Sourced from: https://www.mayoclinic.org/drugs-supplements/hydroxyprogesterone-injection-route/description/drg-20074807)
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Austria | Bangladesh | Chile | China | Egypt | France | Greece | India | Ireland | Pakistan | Russia | Taiwan | Thailand | Turkey | United Arab Emirates | United States
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/21/2026 |
News Article |
Blueprint Equity Raises $333M Fund III, Doubling Down on Enterprise Software, B2B, and Technology-Enabled Services Businesses Worldwide |
|
10/15/2025 |
News Article |
/C O R R E C T I O N -- The Sohn Conference Foundation/ |
|
10/15/2025 |
News Article |
16th Annual Sohn San Francisco Investment Conference to Convene Leading Investors and Support Local Nonprofits |
|
09/08/2025 |
News Article |
Progesterone Market Size Drives at 12.74% CAGR to Hit USD 5.05 Billion by 2034 |